The invention relates to .beta.-alanine derivatives of the formula I ##STR2##
in which Q.sub.1, Q.sub.2, Q.sub.3 or Q.sub.4 is, in each case, independently of one another, CH or N, R.sup.1 is H, A, Ar, Hal, OH, OA, CF.sub.3 or OCF.sub.3, R.sup.2 is H or A, ##STR3## R.sup.4 and R.sup.5 are, in each
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to certain 3-(heteroaryl)alanine derivatives which inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4.
References
The following publications, patents and patent applications are cited in this
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to certain 3-(heteroaryl)alanine derivatives which inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4.
REFERENCES
The following publications, patents and patent applications are cited in this
BACKGROUND OF THE INVENTION
Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not applicable
BACKGROUND OF THE INVENTION
Cancer is the second leading cause of death behind heart disease. In fact, cancer incidence and death figures account for about 10% of the U.S. population in certain
This application claims the benefit of Korean Patent Application No 10-2016-0099978, filed Aug. 5, 2016, the entirety of which is incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to a pharmaceutical composition for preventing or treating liver cancer containing
FIELD
This invention relates to methods of treating cancer in a subject in need thereof.
BACKGROUND
The expanding development and use of targeted therapies for cancer treatment reflects an increasing understanding of key oncogenic pathways, and how the targeted perturbation of these pathways
FIELD OF THE INVENTION
The present invention is directed to a composition for treating early stages of various forms of malignancies, particularly melanoma and lung cancer, in mammals. In more advanced stages of malignancies, such as those involving larger tumors and/or metastases, the composition
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a national phase application under 35 U.S.C. .sctn.371 of International Application No. PCT/EP2014/050330 filed 9 Jan. 2014, which claims priority to European Patent Application No. 13150974.7 filed 11 Jan. 2013. The entire contents of each
The present invention relates to an isolated peptide exhibiting antitumoral effects.
Every year millions of people are diagnosed with cancer worldwide. Notwithstanding in the last decades much progress has been achieved in cancer therapy, nevertheless cancer remains a leading cause of death.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national phase of International Application No. PCT/CN2016/100989, titled "A NEW TYPE POLYPEPTIDE TARGETING TUMOURS", which claims the priority of Chinese Patent Application No. 201510650649.2, filed on Oct. 10, 2015 with the State
FIELD OF THE INVENTION
The invention relates to agents for the inhibition of the growth and/or proliferation of cancer cells.
BACKGROUND OF THE INVENTION
Integrins comprise a family of cell adhesion receptors composed of alpha/beta heterodimeric subunits that provide a functional and structural
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to .beta.-alanine esters of camptothecin compounds which inhibit the enzyme topoisomerase I and have anticancer activity. This invention is also related to the treatment of tumors in animals with camptothecin compounds.
2.
FIELD OF THE INVENTION
The present invention relates to a labelled compound and a method for manufacturing the compound. More particularly, the present invention relates to a compound labelled with radionuclide such as positron nuclide or stable isotope. The labelled compound of the invention is
TECHNICAL FIELD
The present invention relates to peptide derivatives exhibiting pharmaceutical activities such as analgesic activity through action on opioid receptors and the like.
BACKGROUND ART
The existence of opioid receptors to which opioids such as morphine bind was verified in the early
Den mest komplette databasen med medisinske urter støttet av vitenskap
Fungerer på 55 språk
Urtekurer støttet av vitenskap
Urtegjenkjenning etter bilde
Interaktivt GPS-kart - merk urter på stedet (kommer snart)
Les vitenskapelige publikasjoner relatert til søket ditt
Søk medisinske urter etter deres effekter
Organiser dine interesser og hold deg oppdatert med nyheter, kliniske studier og patenter
Skriv inn et symptom eller en sykdom og les om urter som kan hjelpe, skriv en urt og se sykdommer og symptomer den brukes mot. * All informasjon er basert på publisert vitenskapelig forskning